Why Icosavax's Shares Are Trading Lower Today

  • Icosavax Inc ICVX has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).
  • In the naïve setting, adjuvant effect on immunogenicity and a dose-response were observed with IVX-411. However, the level of immune response was comparable to or below the Human Convalescent Sera (HCS) control.
  • At day 49, responses were up to 154 IU/mL across dosage groups in the live virus neutralization assay (HCS: 281 IU/mL) and up to 592 BAU/mL across groups in the spike IgG assay (HCS: 361 BAU/mL).
  • Pre-versus post-boost fold increases of up to 5x (599 IU/mL) for wild-type virus were observed at day 28 post boost.
  • For the omicron variant, neutralizing antibody titers were up to 8-fold lower than observed for wild-type virus.
  • IVX-411 was generally safe and well-tolerated. Solicited local and systemic adverse events (AEs) were mild or moderate, without dose-limiting reactogenicity.
  • Icosavax will share interim data from the lead RSV program, IVX-121, in 2Q 2022, 
  • It expects to initiate Phase 1 trial of the combination vaccine candidate, IVX-A12 against RSV and human metapneumovirus, in 2H 2022.
  • Price Action: ICVX shares are down 16.8% at $10.35 during the premarket session on the last check Friday
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!